Dr. Chinazo Cunningham is the principal investigator in a potentially groundbreaking study into whether marijuana use could reduce the need for addictive opioids in pain management. It’s a rare opportunity given the federal restrictions on studying marijuana. Since 1970, it’s been listed as a Schedule I drug, meaning it has no medical use and there is a high potential for abuse. Despite 30 states legalizing medical marijuana, the federal government maintains there’s not enough research to suggest it has medical benefits, and this position keeps pot from being studied by researchers. Dr. Cunningham joins Soledad O’Brien to talk about her study and the Catch-22 of studying marijuana in the U.S.
Searching for “Forgotten America”
November 26, 2016Searching for “Forgotten America”
November 26, 2016
December 14, 2019
December 21, 2019December 14, 2019
December 21, 2019
Remote Area Medical’s traveling clinics reveal a big problem with America’s health care system
December 14, 2019Remote Area Medical’s traveling clinics reveal a big problem with America’s health care system
December 14, 2019
No Insurance Needed: Pittsburgh doctor takes a flat-fee approach to medicine with $35 fee
November 2, 2019No Insurance Needed: Pittsburgh doctor takes a flat-fee approach to medicine with $35 fee
November 2, 2019
November 2, 2019
November 9, 2019November 2, 2019
November 9, 2019
A TEEN WITH AUTISM HELPING POLICE LEARN TO HELP THOSE IN A MENTAL HEALTH CRISIS
March 30, 2019A TEEN WITH AUTISM HELPING POLICE LEARN TO HELP THOSE IN A MENTAL HEALTH CRISIS
March 30, 2019
America’s Farmers Facing Both Financial and Mental Health Crises
March 23, 2019America’s Farmers Facing Both Financial and Mental Health Crises
March 23, 2019
Thousands of Veterans Suffering After Toxic Smoke Exposure
March 16, 2019Thousands of Veterans Suffering After Toxic Smoke Exposure
March 16, 2019
A Dream Deferred? Undocumented Asian immigrants speak up as DACA's future remains uncertain
December 7, 2019A Dream Deferred? Undocumented Asian immigrants speak up as DACA's future remains uncertain
December 7, 2019
